GlassScriptPhysician profile
Vinh T Cam
NPI 1144243908
$84,837.75
in general payments reported to CMS, 2019-2025
46 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $4,148 · 2021: $6,364 · 2022: $4,259 · 2023: $3,663 · 2024: $32K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,950 · Travel and Lodging: $3,380 · Consulting Fee: $3,300 · Education: $45.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,327.50 |
| Food and Beverage | $12,842.82 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,950.00 |
| Travel and Lodging | $3,379.60 |
| Consulting Fee | $3,300.00 |
| Education | $45.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,294.90 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $14,349.43 | 2020-2025 | Jardiance |
| Travere Therapeutics, INC. | $13,117.48 | 2020-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $11,129.27 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $7,057.49 | 2019-2025 | Veltassa, Korsuva |
| Horizon Therapeutics Plc | $2,481.79 | 2019-2023 | Krystexxa |
| Amgen INC. | $1,553.78 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Otsuka America Pharmaceutical, INC. | $1,430.05 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $1,209.53 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $1,117.14 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $976.12 | 2021-2025 | Ozempic, Wegovy, Rivfloza |
| Akebia Therapeutics INC | $925.88 | 2019-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $828.22 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $824.48 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $724.45 | 2019-2025 | Rayaldee |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinh Cam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.